Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +55.5% | +46.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | +406.3% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +55.5% over three years. Forward estimates point to EBIT at +406.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Travere Therapeutics, Inc. NASDAQ:TVTX | $4.86B | $50.65 | Overvalued | -235.0 | +41.80% |
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -62.99% |
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | $1.64B | $16.08 | Not rated | -4.6 | -44.35% |
Pharming Group N.V. NASDAQ:PHAR | $891.80M | $12.60 | Not rated | 77.0 | -22.51% |
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | $796.97M | $1.79 | Not rated | -30.5 | +18.62% |
Zevra Therapeutics, Inc. NASDAQ:ZVRA | $540.30M | $9.08 | Overvalued | 6.1 | -4.13% |
DiaMedica Therapeutics Inc. NASDAQ:DMAC | $474.01M | $8.79 | Not rated | -8.8 | +17.67% |
Fennec Pharmaceuticals Inc. NASDAQ:FENC | $407.48M | $11.62 | Not rated | -36.3 | +62.96% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -7.06% |
Continue the stock analysis
Jump to another research area for this company.